Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Emerging COVID serology market ripe for disruption
View:
Post by Gbathat on May 29, 2021 8:16am

Emerging COVID serology market ripe for disruption

From Mayo Clinic:

Results of COVID-19 antibody tests may not always be accurate, especially if the test was done too soon after infection or the test quality is questionable. Many different manufacturers rushed to put antibody tests on the market with little oversight. Now the U.S. Food and Drug Administration posts data online about the performance of certain antibody tests.
Comment by Gbathat on May 29, 2021 8:20am
FDA templates for their review process updated/posted as recently as March 24, 2021! My guess is this is the last approval we are waiting on/expecting soon.  These capabilities look eerily/awesomely familiar!!! https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas Serology/Antibody Templates ...more  
Comment by retiredcop on May 30, 2021 4:02pm
This most recent view by the FDA on antibody tests , could be one of the main reasons that PMN recently made it very, very clear that their test will not be available for use by the public or doctors for determining immunity on covid whether from vaccine or previous infection. . Instead the tests are for research and information gathering purposes by vaccine producers and various govt groups ...more  
Comment by Gbathat on May 30, 2021 6:27pm
Thanks for sharing this link. Could be a speed bump or could be a table setter for the PMN/BCNI test, given that they have been studying this correlation for a year or so.  But it would explain the language in the recent PR. I still think the March 17 FDA posting of the Template for Test Developers of Serology Tests that Detect or Correlate to Neutralizing Antibodies (March 17, 2021)  ...more  
Comment by Mole101 on May 30, 2021 7:43pm
  It was mention , here is the  The antibody test developed by BC Neuroimmunology (BCNI) Laboratory is based on the use of surface plasmon resonance (SPR) technology, a sophisticated nanotechnology platform that offers advantages compared to ELISA (enzyme-linked immunosorbent assay), the current standard for assay creation. The current version of the ProMIS-BCNI antibody test ...more  
Comment by DavidKingCanada on May 31, 2021 2:11am
It will be very interesting to see what PMN can bring to the table come this week!
Comment by BottomBroker on May 31, 2021 8:57am
I would be extremely suprised if Promis is influencing any process by the FDA.  But it would be nice if it was true. 
Comment by M101 on May 31, 2021 3:00pm
Sure, they'd send over a couple of escorts. Maybe not Epstein grade but you know whatever Elliot figured shareholders here could afford. JMO.    
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities